Management ChangeJul 9, 2026, 08:02 AM
Vera Therapeutics Announces Chief Regulatory Officer Transition
AI Summary
Vera Therapeutics announced a planned transition for its Chief Regulatory Officer position. William Turner, who successfully oversaw the accelerated approval of TRUTAKNA™ for IgA nephropathy, will retire and move into a Strategic Advisor role in the third quarter. Nancy Boman, M.D., Ph.D., with over 25 years of regulatory affairs experience from companies like Kyverna Therapeutics and Novartis Gene Therapies, will take over as the new Chief Regulatory Officer. The company anticipates Dr. Boman's expertise will be invaluable for pursuing new indications for TRUTAKNA and developing other pipeline molecules.
Key Highlights
- William Turner, current Chief Regulatory Officer, will retire and become Strategic Advisor in Q3.
- Turner led the regulatory strategy for the accelerated approval of TRUTAKNA™ (atacicept-vymj).
- Nancy Boman, M.D., Ph.D., will succeed Mr. Turner as Chief Regulatory Officer.
- Dr. Boman brings over 25 years of regulatory affairs experience, including from Kyverna and Novartis Gene Therapies.
- Dr. Boman's expertise is expected to aid new indications for TRUTAKNA and pipeline development.
Price Impact
More from VERA